verucerfont
Small moleculeexperimental
Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRH-1 and CRH-2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. — Wikipedia
Clinical trial activity
9 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00426608)
Timeline
Indications
Mechanism of action
CRHR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](Nc1cc(C)nc2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1- Mol. weight
- 406.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVerucerfont ↗
- ChEMBLCHEMBL1287935 ↗
Also known as
- gsk561679
- gsk561679
- gsk561679
- gsk561679
- gsk 561679
- gsk-561679
- gsk561679a
- gsk561679a
- nbi77860
- nbi 77860
- nbi-77860
- nbi-77860
- nbi-77860
- nbi-77860
- verucerfont
- verucerfont
- verucerfont
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02349503 | Phase 1 | Feb 1, 2015 | Neurocrine Biosciences |
| NCT01814332 | Phase 2 | Jan 1, 2010 | Department of Veteran Affairs |
| NCT01187511 | Phase 2 | Jan 1, 2010 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT01018992 | Phase 2 | Dec 1, 2009 | Emory University, Icahn School of Medicine at Mount Sinai |
| NCT00733980 | Phase 2 | Oct 1, 2008 | GlaxoSmithKline |
| NCT00539136 | Phase 1 | Oct 1, 2007 | GlaxoSmithKline |
| NCT00511563 | Phase 2 | Aug 1, 2007 | GlaxoSmithKline |
| NCT00555139 | Phase 1 | Mar 1, 2007 | GlaxoSmithKline |
| NCT00426608 | Phase 1 | Oct 1, 2006 | GlaxoSmithKline |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2006 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2010 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2009 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 1 | 1 | 2010 |
| Neurocrine Biosciences | For profit | 1 | 1 | 1 | 2015 |
6 organizations
Page 1 / 1